The release of the snapshot containing the respective simulations can be found here:
https://github.com/Open-Systems-Pharmacology/Erythromycin-Carbamazepine-DDI/releases/tag/v1.1

The erythromycin-carbamazepine interaction was evaluated using three clinical DDI studies ([Barzaghi 1987](#4-references), [Miles 1989](#4-references), [Wong 1983](#4-references)).

| DataID | Enzyme | Perpetrator / victim         | Study design                                                                                                                                             | Clinical study                 |
| ------ | ------ | ---------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------ |
| 465    | CYP3A4 | Erythromycin / carbamazepine | Erythromycin: 500 mg po TID for 10 days<br />Carbamazepine: 400 mg po single dose, administered on the 7<sup>th</sup> day of treatment with erythromycin | [Barzaghi 1987](#4-references) |
| 1157   | CYP3A4 | Erythromycin / carbamazepine | Erythromycin: 250 mg po QID for 3 days, starting on day 15 of carbamazepine administration<br />Carbamazepine: 300 mg po QD for 17 days                  | [Miles 1989](#4-references)    |
| 1158   | CYP3A4 | Erythromycin / carbamazepine | Erythromycin: 250 mg po QID for 3 days, starting on day 15 of carbamazepine administration<br />Carbamazepine: 400 mg po QD for 17 days                  | [Miles 1989](#4-references)    |
| 1154   | CYP3A4 | Erythromycin / carbamazepine | Erythromycin: 250 mg po QID for 8 days<br />Carbamazepine: 400 mg po single dose, administered on the 6<sup>th</sup> day of treatment with erythromycin  | [Wong 1983](#4-references)     |
